Clinical Research Directory
Browse clinical research sites, groups, and studies.
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Sponsor: Alnylam Pharmaceuticals
Summary
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
Official title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2019-09-12
Completion Date
2027-03-15
Last Updated
2026-01-12
Healthy Volunteers
No
Interventions
Placebo
Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
Patisiran
Patisiran will be administered by intravenous (IV) infusion.
Locations (90)
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Skokie, Illinois, United States
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Kansas City, Kansas, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Burlington, Massachusetts, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
St Louis, Missouri, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Pittsburgh, Pennsylvania, United States
Clinical Trial Site
Nashville, Tennessee, United States
Clinical Trial Site
Dallas, Texas, United States
Clinical Trial Site
Norfolk, Virginia, United States
Clinical Trial Site
Buenos Aires, Buenos Aires, Argentina
Clinical Trial Site
San Juan Bautista, Buenos Aires, Argentina
Clinical Trial Site
Córdoba, Córdoba Province, Argentina
Clinical Trial Site
Rosario, Santa Fe Province, Argentina
Clinical Trial Site
Rosario, Santa Fe Province, Argentina
Clinical Trial Site
Rosario, Santa Fe Province, Argentina
Clinical Trial Site
Santa Fe, Santa Fe Province, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Westmead, New South Wales, Australia
Clinical Trial Site
Woolloongabba, Queensland, Australia
Clinical Trial Site
Box Hill, Victoria, Australia
Clinical Trial Site
Liège, LIE, Belgium
Clinical Trial Site
Hasselt, LIM, Belgium
Clinical Trial Site
Aalst, OVL, Belgium
Clinical Trial Site
Roeselare, WVL, Belgium
Clinical Trial Site
Porto Alegre, Rio Grande do Sul, Brazil
Clinical Trial Site
Ribeirão Preto, São Paulo, Brazil
Clinical Trial Site
Ribeirão Preto, São Paulo, Brazil
Clinical Trial Site
São Paulo, São Paulo, Brazil
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
São Paulo, Brazil
Clinical Trial Site
Sofia, Sofia-Grad, Bulgaria
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Stara Zagora, Bulgaria
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Prague, Praha, Hlavní Mesto, Czechia
Clinical Trial Site
Brno, Czechia
Clinical Trial Site
Prague, Czechia
Clinical Trial Site
Prague, Czechia
Clinical Trial Site
Aarhus N, Aarhus, Denmark
Clinical Trial Site
Copenhagen, Denmark
Clinical Trial Site
Odense C, Denmark
Clinical Trial Site
Clichy, Paris, France
Clinical Trial Site
Créteil, Val-de-Marne, France
Clinical Trial Site
Rennes, France
Clinical Trial Site
Toulouse, France
Clinical Trial Site
Lai Chi Kok, Hong Kong
Clinical Trial Site
Bologna, Emilia-Romagna, Italy
Clinical Trial Site
Messina, Sicily, Italy
Clinical Trial Site
Florence, Italy
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Nagoya, Aichi-ken, Japan
Clinical Trial Site
Kurume, Fukuoka, Japan
Clinical Trial Site
Matsumoto, Nagano, Japan
Clinical Trial Site
Suita, Osaka, Japan
Clinical Trial Site
Bunkyo-ku, Tokyo, Japan
Clinical Trial Site
Fukuoka, Japan
Clinical Trial Site
Kumamoto, Japan
Clinical Trial Site
Mexico City, Mexico
Clinical Trial Site
Groningen, Netherlands
Clinical Trial Site
Maastricht, Netherlands
Clinical Trial Site
Christchurch, New Zealand
Clinical Trial Site
Hamilton, New Zealand
Clinical Trial Site
Lódz, Lódzkie, Poland
Clinical Trial Site
Warsaw, Masovian Voivodeship, Poland
Clinical Trial Site
Warsaw, Masovian Voivodeship, Poland
Clinical Trial Site
Gdansk, Pomeranian Voivodeship, Poland
Clinical Trial Site
Katowice, Silesian Voivodeship, Poland
Clinical Trial Site
Porto, Portugal
Clinical Trial Site
Senhora da Hora, Portugal
Clinical Trial Site
Viseu, Portugal
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Stockholm, Sweden
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Bellshill, Lanarkshire, United Kingdom
Clinical Trial Site
London, London, City of, United Kingdom
Clinical Trial Site
Hexham, Northumberland, United Kingdom
Clinical Trial Site
Birmingham, West Midlands, United Kingdom
Clinical Trial Site
Cardiff, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Manchester, United Kingdom